Hancock Whitney’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-5,340
Closed -$272K 783
2025
Q4
$272K Sell
5,340
-4,723
-47% -$242K ﹤0.01% 693
2025
Q3
$558K Sell
10,063
-1,320
-12% -$77.3K 0.01% 537
2025
Q2
$786K Buy
11,383
+6,148
+117% +$418K 0.02% 474
2025
Q1
$364K Sell
5,235
-21
-0.4% -$1.73K 0.01% 511
2024
Q4
$452K Sell
5,256
-1,017
-16% -$110K 0.01% 446
2024
Q3
$747K Buy
6,273
+300
+5% +$40K 0.02% 365
2024
Q2
$853K Sell
5,973
-251
-4% -$33.3K 0.03% 332
2024
Q1
$799K Sell
6,224
-631
-9% -$75.1K 0.03% 347
2023
Q4
$709K Buy
6,855
+71
+1% +$7.02K 0.03% 373
2023
Q3
$617K Buy
6,784
+58
+0.9% +$5.11K 0.03% 373
2023
Q2
$544K Buy
6,726
+2,042
+44% +$167K 0.02% 425
2023
Q1
$373K Buy
4,684
+184
+4% +$13K 0.02% 492
2022
Q4
$305K Sell
4,500
-220
-5% -$12.9K 0.01% 533
2022
Q3
$235K Buy
+4,720
New +$253K 0.01% 570
2022
Q2
Sell
-5,008
Closed -$278K 663
2022
Q1
$278K Buy
5,008
+406
+9% +$20.8K 0.01% 602
2021
Q4
$258K Buy
+4,602
New +$249K 0.01% 618
2014
Q4
Sell
-9,726
Closed -$232K 536
2014
Q3
$232K Sell
9,726
-244
-2% -$5.62K 0.01% 464
2014
Q2
$230K Buy
+9,970
New +$220K 0.01% 473

Other funds holding NVO

Hancock Whitney's NVO Position: Q1 2026 in Review

Hancock Whitney sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 5,340 shares — an estimated $272K sold.

Hancock Whitney first reported a position in NVO in Q2 2014 and held it in 18 quarters. The position peaked at $853K in Q2 2024. 1,277 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Hancock Whitney reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
  • Hancock Whitney sold 5,340 Novo Nordisk shares in Q1 2026, an estimated $272K.
  • Hancock Whitney first reported a position in Novo Nordisk in Q2 2014 and held it in 18 quarters.
  • Hancock Whitney's Novo Nordisk position peaked at $853K in Q2 2024.
  • 1,277 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Hancock Whitney's 13F filing for Q1 2026, filed 15 May 2026.